At the time of the primary analysis of overall survival ( median follow-up @ months -LSB- IQR @-@ -RSB- ) , overall survival was significantly greater in the afatinib group than in the erloinib group ( median @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; HR @ -LSB- @ % CI @-@ -RSB- , p = @ ) , as were progression-free survival ( median @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; HR @ -LSB- @ % CI @-@ -RSB- , p = @ ) and disease control ( @ -LSB- @ % -RSB- of @ patients vs @ -LSB- @ % -RSB- of @ ; p = @ ) .